ES2191484T3 - Compuestos heterociclicos como inhibidores de enzimas de rotamasa. - Google Patents
Compuestos heterociclicos como inhibidores de enzimas de rotamasa.Info
- Publication number
- ES2191484T3 ES2191484T3 ES99963123T ES99963123T ES2191484T3 ES 2191484 T3 ES2191484 T3 ES 2191484T3 ES 99963123 T ES99963123 T ES 99963123T ES 99963123 T ES99963123 T ES 99963123T ES 2191484 T3 ES2191484 T3 ES 2191484T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- aryl
- independently selected
- halogen
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 12
- 125000003118 aryl group Chemical group 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- -1 C3-C7 cycloalkyl Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000006574 non-aromatic ring group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto de fórmula (I): **(Fórmula)** o una sal farmacéuticamente aceptable del mismo, en el que A es un alquileno C3 - C5 no ramificado opcionalmente sustituido con un alquilo C1 - C6; X es O, S, NH o N(alquilo C1 - C6); Y es O, S, NH o N(alquilo C1 - C6); R es un grupo heterocíclico de anillo no aromático de 4 a 6 eslabones unido por un átomo de carbono, que contiene un heteroátomo de nitrógeno, estando dicho grupo opcionalmente sustituído con 1, 2, ó 3 sustituyente(s) cada uno de ellos independientemente seleccionado de alquilo C1 - C6, alquenilo C2 - C6, cicloalquilo C3 - C7, arilo, het, - CO2 (alquilo C1 - C6), - CO (het), - CONR5R6 y - CO (arilo), estando dicho alquilo y alquenilo opcionalmente sustituidos por 1 ó 2 sustituyente(s) cada uno de ellos seleccionados independientemente de cicloalquilo C3 - C7, arilo, het, - O (arilo), - O (alquileno C1 - C2)arilo, - CO (het), - CONR5R6 y - CO (arilo); R1, R2, R3 y R4 se seleccionan independientemente de H, halógeno, alquilo C1 - C6,cicloalquilo C3 - C7, haloalquilo C1 - C6), alcoxi C1 - C6, - CONR5R6, cicloalcoxi C3 - C7, cicloalquilo C3 - C7 - alquileno (C2 - C4), cicloalquilo (C3 - C7)alcoxi (C2 - C4) y - CO2(alquilo C1 - C6); R5 y R6 son, bien cada uno de ellos independientemente seleccionados entre H y alquilo C1 - C6, o bien, cuando se consideran juntos, representan un alquileno C3 - C5 no ramificado; ¿arilo¿ significa fenilo, opcionalmente sustituido con 1, 2 ó 3 sustituyente(s) cada uno de ellos independientemente seleccionado entre alquilo C1 - C6, alcoxi C1 - C6, halógeno, CONR5R6, halógeno(alquilo C1 - C6) y - NR5R6; y ¿het¿ significa un grupo heterocíclico de anillo monocíclico de 5 ó 6 eslabones, o de anillo bicíclico de 8, 9 ó 10 eslabones, que contiente de 1 a 3 heteroátomos cada uno de ellos independientemente seleccionado entre N, O y S, dicho grupo puede estar opcionalmente sustituido con 1, 2 ó 3 sustituyente(s) cada uno de ellos seleccionado independientemente entre alquilo C1 - C6, alcoxi C1 - C6,halógeno, halógeno(alquilo C1 - C6), fenilo y - NR5R6.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9815880.1A GB9815880D0 (en) | 1998-07-21 | 1998-07-21 | Heterocycles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2191484T3 true ES2191484T3 (es) | 2003-09-01 |
Family
ID=10835920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99963123T Expired - Lifetime ES2191484T3 (es) | 1998-07-21 | 1999-06-28 | Compuestos heterociclicos como inhibidores de enzimas de rotamasa. |
Country Status (45)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9815696D0 (en) * | 1998-07-20 | 1998-09-16 | Pfizer Ltd | Heterocyclics |
| GB9815880D0 (en) * | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
| ID28787A (id) | 1998-11-03 | 2001-07-05 | Basf Ag | 2-fenilbenzimidazol tersubstitusi, pembuatannya dan penggunaannya |
| CO5261615A1 (es) | 1999-12-01 | 2003-03-31 | Agouron Pharma | Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas |
| FR2805818B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
| DE10124953A1 (de) * | 2001-05-21 | 2002-12-12 | Marlies Knipper | Substanz für die therapeutische Behandlung von Tinnitus |
| ES2383123T3 (es) * | 2004-06-29 | 2012-06-18 | Aventis Pharmaceuticals Inc. | Composición de unión a FKBP y su uso farmacéutico |
| US7728026B2 (en) * | 2005-04-11 | 2010-06-01 | Abbott Laboratories, Inc. | 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors |
| TWI375673B (en) * | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| CN101316834A (zh) * | 2005-09-29 | 2008-12-03 | 艾博特公司 | 在2位取代有苯基的1h-苯并咪唑-4-甲酰胺是强效parp抑制剂 |
| CN101309908A (zh) * | 2005-11-15 | 2008-11-19 | 艾博特公司 | 作为有效parp抑制剂的取代的1h-苯并咪唑-4-甲酰胺化合物 |
| DK1976828T3 (en) | 2005-12-29 | 2017-03-06 | Celtaxsys Inc | DIAMINE DERIVATIVES AS INhibitors of Leukotriene A4 HYDROLASE |
| RU2462458C2 (ru) * | 2006-02-10 | 2012-09-27 | Байомарин Ига Лимитед | Лечение миодистрофии дюшена |
| KR101472248B1 (ko) | 2006-02-10 | 2014-12-16 | 서미트 코포레이션 피엘씨 | 뒤시엔느 근이영양증의 치료 |
| GB0602768D0 (en) * | 2006-02-10 | 2006-03-22 | Vastox Plc | Treatment of muscular dystrophy |
| EP2012780B1 (en) * | 2006-05-02 | 2012-04-11 | Abbott Laboratories | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
| ES2387471T3 (es) | 2006-12-20 | 2012-09-24 | Amgen Inc. | Compuestos heterocíclicos y su uso en el tratamiento de la inflamación, la angiogénesis y el cáncer |
| CL2008000666A1 (es) * | 2007-03-07 | 2008-06-13 | Xenon Pharmaceuticals Inc | Compuestos derivados de triciclos sustituidos, inhibidores del transportador de metales divalentes-1; y uso para tratar una enfermedad asociada con un trastorno del hierro. |
| US8067613B2 (en) * | 2007-07-16 | 2011-11-29 | Abbott Laboratories | Benzimidazole poly(ADP ribose)polymerase inhibitors |
| AR068332A1 (es) * | 2007-08-03 | 2009-11-11 | Summit Corp Plc | Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne |
| GB0715939D0 (en) * | 2007-08-15 | 2007-09-26 | Vastox Plc | Method of treatment of duchenne muscular dystrophy |
| GB0715937D0 (en) * | 2007-08-15 | 2007-09-26 | Vastox Plc | Method of treatment og duchenne muscular dystrophy |
| DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
| WO2010083199A1 (en) * | 2009-01-19 | 2010-07-22 | Abbott Laboratories | Benzthiazole inhibitors of poly(adp-ribose)polymerase |
| GB0905664D0 (en) * | 2009-04-02 | 2009-05-13 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| ES2864862T3 (es) | 2013-03-12 | 2021-10-14 | Celltaxis Llc | Métodos de inhibición de la leucotrieno A4 hidrolasa |
| CA2906035A1 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
| RU2690489C2 (ru) | 2013-03-14 | 2019-06-04 | Селтакссис, Инк. | Ингибиторы лейкотриен а4-гидролазы |
| WO2014152518A2 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
| AR100530A1 (es) * | 2014-05-19 | 2016-10-12 | Merial Inc | Compuestos antihelmínticos |
| WO2019232306A1 (en) | 2018-05-31 | 2019-12-05 | Celtaxsys, Inc. | Method of reducing pulmonary exacerbations in respiratory disease patients |
| CN109111376B (zh) * | 2018-09-18 | 2021-09-14 | 四川医立特生物医药有限公司 | 一种2,5-双脱氧链霉胺衍生物及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612332A (en) * | 1984-03-19 | 1997-03-18 | Alteon Inc. | Di- and triaminoguanidines, and methods of use |
| JPS6428245A (en) | 1987-07-22 | 1989-01-30 | Sumitomo Electric Industries | Production of fluoride glass |
| MX9202466A (es) | 1991-05-24 | 1994-06-30 | Vertex Pharma | Compuestos inmunosupresores novedosos. |
| CO4520280A1 (es) * | 1993-10-26 | 1997-10-15 | Boehringer Ingelheim Pharma | Derivados de pirrolidina, inhibidores de la bioscientesis de leucotrienos |
| DE19514313A1 (de) | 1994-08-03 | 1996-02-08 | Bayer Ag | Benzoxazolyl- und Benzothiazolyloxazolidinone |
| US5859031A (en) | 1995-06-07 | 1999-01-12 | Gpi Nil Holdings, Inc. | Small molecule inhibitors of rotamase enzyme activity |
| US5696135A (en) * | 1995-06-07 | 1997-12-09 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth |
| US5801197A (en) * | 1995-10-31 | 1998-09-01 | Gpi Nil Holdings, Inc. | Rotamase enzyme activity inhibitors |
| US5786378A (en) * | 1996-09-25 | 1998-07-28 | Gpi Nil Holdings, Inc. | Heterocyclic thioesters |
| US5801187A (en) * | 1996-09-25 | 1998-09-01 | Gpi-Nil Holdings, Inc. | Heterocyclic esters and amides |
| US5840736A (en) | 1996-11-13 | 1998-11-24 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
| US5780484A (en) | 1996-11-13 | 1998-07-14 | Vertex Pharmaceuticals Incorporated | Methods for stimulating neurite growth with piperidine compounds |
| US5811434A (en) | 1996-11-13 | 1998-09-22 | Vertex Pharmacueticals Incorporated | Methods and compositions for stimulating neurite growth |
| US5721256A (en) | 1997-02-12 | 1998-02-24 | Gpi Nil Holdings, Inc. | Method of using neurotrophic sulfonamide compounds |
| GB9815696D0 (en) * | 1998-07-20 | 1998-09-16 | Pfizer Ltd | Heterocyclics |
| GB9815880D0 (en) * | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
-
1998
- 1998-07-21 GB GBGB9815880.1A patent/GB9815880D0/en not_active Ceased
-
1999
- 1999-06-28 CN CNA2003101239079A patent/CN1511837A/zh active Pending
- 1999-06-28 SI SI9930246T patent/SI1100797T1/xx unknown
- 1999-06-28 AT AT99963123T patent/ATE233261T1/de not_active IP Right Cessation
- 1999-06-28 DE DE69905582T patent/DE69905582T2/de not_active Expired - Fee Related
- 1999-06-28 BR BR9912330-4A patent/BR9912330A/pt not_active Application Discontinuation
- 1999-06-28 AU AU42858/99A patent/AU765925B2/en not_active Ceased
- 1999-06-28 KR KR10-2004-7007852A patent/KR100468185B1/ko not_active Expired - Fee Related
- 1999-06-28 NZ NZ522270A patent/NZ522270A/en unknown
- 1999-06-28 HU HU0103413A patent/HUP0103413A3/hu unknown
- 1999-06-28 CA CA002338214A patent/CA2338214C/en not_active Expired - Fee Related
- 1999-06-28 ID IDW20010155A patent/ID26991A/id unknown
- 1999-06-28 EP EP99963123A patent/EP1100797B1/en not_active Expired - Lifetime
- 1999-06-28 EE EEP200100044A patent/EE200100044A/xx unknown
- 1999-06-28 TR TR2001/00135T patent/TR200100135T2/xx unknown
- 1999-06-28 CN CNB998089974A patent/CN1174978C/zh not_active Expired - Fee Related
- 1999-06-28 HK HK02100933.8A patent/HK1039779A1/zh unknown
- 1999-06-28 DK DK99963123T patent/DK1100797T3/da active
- 1999-06-28 CN CNA2004100399747A patent/CN1611499A/zh active Pending
- 1999-06-28 GE GEAP19995715A patent/GEP20033028B/en unknown
- 1999-06-28 OA OA1200100023A patent/OA11585A/en unknown
- 1999-06-28 JP JP2000561188A patent/JP3795329B2/ja not_active Expired - Fee Related
- 1999-06-28 SK SK77-2001A patent/SK772001A3/sk unknown
- 1999-06-28 PL PL99345734A patent/PL345734A1/xx not_active Application Discontinuation
- 1999-06-28 ES ES99963123T patent/ES2191484T3/es not_active Expired - Lifetime
- 1999-06-28 HR HR20010052A patent/HRP20010052A2/hr not_active Application Discontinuation
- 1999-06-28 NZ NZ508838A patent/NZ508838A/xx unknown
- 1999-06-28 KR KR10-2001-7000927A patent/KR100450008B1/ko not_active Expired - Fee Related
- 1999-06-28 AP APAP/P/2001/002046A patent/AP2001002046A0/en unknown
- 1999-06-28 EA EA200100052A patent/EA003513B1/ru not_active IP Right Cessation
- 1999-06-28 IL IL14024499A patent/IL140244A0/xx unknown
- 1999-06-28 WO PCT/IB1999/001211 patent/WO2000005232A1/en not_active Application Discontinuation
- 1999-07-07 HN HN1999000106A patent/HN1999000106A/es unknown
- 1999-07-13 TW TW088111868A patent/TWI229672B/zh not_active IP Right Cessation
- 1999-07-19 CO CO99045677A patent/CO5080782A1/es unknown
- 1999-07-19 AR ARP990103544A patent/AR019427A1/es unknown
- 1999-07-20 MA MA25691A patent/MA24936A1/fr unknown
- 1999-07-20 SV SV1999000102A patent/SV1999000102A/es not_active Application Discontinuation
- 1999-07-20 PA PA19998478501A patent/PA8478501A1/es unknown
- 1999-07-20 CR CR6073A patent/CR6073A/es not_active Application Discontinuation
- 1999-07-20 DZ DZ990151A patent/DZ2851A1/xx active
- 1999-07-20 PE PE1999000727A patent/PE20001037A1/es not_active Application Discontinuation
- 1999-07-20 GT GT199900115A patent/GT199900115A/es unknown
- 1999-07-20 TN TNTNSN99147A patent/TNSN99147A1/fr unknown
- 1999-07-20 MY MYPI99003048A patent/MY118222A/en unknown
- 1999-07-21 US US09/358,107 patent/US6372736B1/en not_active Expired - Fee Related
-
2000
- 2000-12-22 IS IS5790A patent/IS5790A/is unknown
-
2001
- 2001-01-19 NO NO20010322A patent/NO20010322L/no not_active Application Discontinuation
- 2001-02-14 BG BG105254A patent/BG105254A/xx unknown
-
2002
- 2002-01-23 US US10/056,901 patent/US6562964B1/en not_active Expired - Fee Related
-
2003
- 2003-04-09 JP JP2003105099A patent/JP2004002374A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2191484T3 (es) | Compuestos heterociclicos como inhibidores de enzimas de rotamasa. | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| AR117916A1 (es) | Compuesto heterocíclico y su uso | |
| DK0606024T3 (da) | Erythromycinderivater, en fremgangsmåde til deres fremstilling samt deres anvendelse som lægemidler | |
| RS52397B (en) | PYRIDO / 2,1-A / ISOCHINOLINE DERIVATIVES AS DPP-IV INHIBITORS | |
| AR035548A1 (es) | Compuestos organicos | |
| PE20010152A1 (es) | Derivados heterociclicos utiles como agentes anticancerosos | |
| AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
| CO5721002A2 (es) | Derivados de acido 3-(4-benciloxifenil) propanoico | |
| ES2179490T3 (es) | Derivados de 1,2,4-triazolo(3,4-a)ftalazina sustituidos como ligandos de gaba alfa 5. | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| ES2196772T3 (es) | Compuestos amino ciclicos. | |
| CO5640140A2 (es) | Inhibidores de actividad de akt | |
| AR055144A1 (es) | Inhibidor de secrecion acida | |
| CO5160347A1 (es) | Derivados de acido carbamico | |
| AR040031A1 (es) | Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen | |
| AR006720A1 (es) | Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende | |
| DK1020439T3 (da) | Inhibitorer af CETP-aktivitet | |
| WO2007149448A3 (en) | Pyrazinones as cellular proliferation inhibitors | |
| AR031597A1 (es) | Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3 | |
| CO6331462A2 (es) | Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa | |
| ECSP066415A (es) | 2-carbonilamino-6-piperidinaminopiridinas sustituidas y 1-carbonilamino-3-piperidinaminobenzenos sustituidos como 5-ht1f agonistas | |
| CO4990932A1 (es) | Derivados de 2,1,3-benzotiadiazol y proceso para su preparacion | |
| DK1031569T3 (da) | Salt af et 7-isoindolinquinoloncarboxylsyre-derivat, monohydrat deraf og sammensætning, der indeholder dette som aktiv bestanddel | |
| CO4900047A1 (es) | Amidas del acido 4-(n -benzoilamino)-penten-2-enoico que tienen actividad como antagonistas de neuroquinina |